CN107456612A - Submucosal injection solution - Google Patents
Submucosal injection solution Download PDFInfo
- Publication number
- CN107456612A CN107456612A CN201610389190.XA CN201610389190A CN107456612A CN 107456612 A CN107456612 A CN 107456612A CN 201610389190 A CN201610389190 A CN 201610389190A CN 107456612 A CN107456612 A CN 107456612A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- injection solution
- submucosal injection
- sodium hyaluronate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention provides a kind of submucosal injection solution, including the parts by weight of Sodium Hyaluronate 0.1 3.0, the parts by weight of coloring agent 0.001 0.02 and the parts by weight of water 90 99, and the coloring agent is the one or more in indicarminum, toluidine blue, phenol red, Congo red, crystal violet.Submucosal injection solution good fluidity of the present invention, protuberance effect are held time length, and Sodium Hyaluronate therein can play the barrier iris action of machinery；Lubrication is good, can reduce esophagus, and the foreign matter in stomach, enteron aisle is to the friction in wound healing process；Mitigate the infiltration of local inflammation reaction and inflammatory cell, mitigate and suppress bleeding and oozing of blood；Diaphragm is formed on serous coat, and retains the long period, so that the serous coat of organ surface covering is preferably repaired；By influenceing immunocyte, the activity of cell factor play its immunoregulation effect, have and promote vascularization, promote the physiological functions such as wound healing, antitumor, immunological regulation.
Description
Technical field
The present invention relates to a kind of submucosal injection solution.
Background technology
Endoscopic submucosal dissection (Endoscopic submucosal dissection, ESD) be the nineties in last century by
One kind that Japanese scholars developed on the basis of scope mucosectomy (EMR) collect Clinics and Practices early carcinoma of stomach in
The digestive endoscope technology of one.Studies have shown that is treated relative to traditional abdominal, therapeutic endoscopy to tumour one
Secondary property resection rate is very high, and can effectively avoid the complication such as infection of incisional wound, otch cracking, dumping syndrome, has invasion and attack
Property it is small the characteristics of, in the pain in mitigating patient treatment procedure, improve patients ' life quality in terms of there is significantly advantage,
The advantages of minimally invasive is fully demonstrated.Meanwhile ESD can also obtain complete Pathologic specimen, the development for diagnosing tumour
Stage and prevention recurrence are significant.
There are more clinical practice and document report in Japan and South Korea, RSD, especially in Japan, therapeutic endoscopy is
It is widely accepted, and as the standard art formula of early-stage cancer treatment.In order that the process of Endoscopic submucosal dissection is more pacified
Entirely, operated quickly and conveniently, it will usually in the submucosa and surrounding injection submucosal injection liquid of focus, by mucous layer and muscle layer
Separate and swell, facilitate the disposable intactly removal of lesions of operator to reduce perforation and bleeding etc. without damaging muscularis propria
The risk of complication.Therefore, smoothly implementation of the submucosal injection liquid to ESD is significant.
At present, the submucosal injection liquid clinically commonly used has physiological saline, hypertonic saline, Glycerin Fructose.Physiological saline is made
It is not only cheap, safe, simple and be easily obtained for submucosal injection medium, and to organizing entirely without damage, have
Preferable clinical effectiveness.But the major defect of physiological saline is easily to absorb, and liquid cushion praises the maintenance in submucosa
Ability is poor, and in ESD therapeutic process, the especially focus row ESD at operating difficulties position needs repeatedly when treating
Multiple submucosal injection, to maintain Submucosal masses, influence the success rate of ESD operations.
Hypertonic saline can make up the defects of physiological saline needs submucosal injection repeatedly, but research has shown that to apply hypertonic saline
During as submucosal injection medium, it is observed that the inflammatory reaction of severe and substantial amounts of tissue damage, these shortcomings can show
Writing influences the success rate of Endoscopic removal focus, can trigger surface of a wound ulcer, cause wound healing bad.
Glycerin Fructose is to be dissolved in the hypertonicity solution formed in physiological saline by 10% glycerine and 5% fructose, clinically by
Permeability dehydrating agent as encephaledema, and one kind effectively selection of submucosal injection medium, are applied in ESD arts
Glycerin Fructose mixed liquor submucosal injection, it can preferably keep liquid cushion under mucous membrane, there is good security, can conduct
Submucosal injection medium in ESD arts.Sticked it will be appreciated that being peeled off during ESD using TURP coagulation pattern
During film undertissue, smog severe jamming scope visual area caused by Glycerin Fructose ionization influences being smoothed out for operation.
Number of patent application：201280052159.7 a kind of Submucosal masses agent is disclosed, by using xanthans, Irish moss
Glue, gellan gum, guar gum, locust bean gum, Sacran etc. have the polysaccharide of pseudoplastic behavior viscosity as protuberance agent, solution
Determine when protuberance agent applies compressing to the position of protuberance and easily deformed, and the degree swelled is also low, injects afterwale
Agent is diffused into perienchyma and causes protuberance to disappear at once, and the problem of be difficult to reliably cut off target site.
Number of patent application：It is the water of sodium indigotindisulfonate 201410035855.8 disclosing a kind of alimentary canal mucous membrane coloring agent
Solution.The gastrointestinal tract mucosa coloring agent can be deposited in the surface and anterior pituitary-adrenal cortex axis of gastrointestinal tract mucosa, make coloring mucous membrane surface
Made a sharp contrast with non-staining part.The not colored bump between anterior pituitary-adrenal cortex axis, it is easy to rinse, can be repeatedly
Dyeing is until satisfied.The mucosa staining agent has the characteristics of not absorbed and had no side effect by gastrointestinal mucosa.
The content of the invention
It is an object of the invention to provide a kind of good fluidity, viscosity are low, in ESD therapeutic process, when protuberance effect maintains
Between it is long, postoperative recovery effect is good, the high submucosal injection solution of the success rate of operation.
The technical scheme is that：
Submucosal injection solution, including Sodium Hyaluronate 0.1-3.0 parts by weight, coloring agent 0.001-0.02 parts by weight and water
90-99 parts by weight, the coloring agent are the one or more in indicarminum, toluidine blue, phenol red, Congo red, crystal violet.
Hyaluronic acid is a kind of acid mucopolysaccharide found in connective tissue, and Columbia Univ USA's ophthalmology is taught within 1934
Award Meyer etc. and isolate the material from bovine vitreous body first.Hyaluronic acid is with its unique molecular structure and physics and chemistry
Matter shows a variety of important physiological functions in body, has the characteristic of nontoxic, no antigen and less injury tissue,
Normal tissue not damaged acts on.
Sodium Hyaluronate 0.1-3.0 parts by weight and water 90-99 parts by weight are added in submucosal injection solution of the present invention, it flows
Dynamic property is good, viscosity is low, and protuberance effect is held time length, can ensure smooth implementation of performing the operation, need not in surgical procedure
Inject repeatedly, it is easy to operate.
In addition, Sodium Hyaluronate after being expelled under mucous membrane, can form macromolecular network structure, the barrier of machinery is played
Iris action；There is preferable lubrication, can reduce esophagus, the foreign matter in stomach, enteron aisle is in wound healing process
Friction；Mitigate the infiltration of local inflammation reaction and inflammatory cell, mitigate and suppress bleeding and oozing of blood；Sodium Hyaluronate may be used also
Diaphragm is formed on serous coat, and retains the long period, so that the serous coat of organ surface covering is preferably repaired.
The present inventor also found Sodium Hyaluronate meeting after injecting under mucous membrane in submucosal injection solution of the present invention under study for action
In vivo by the HA polymer catabolites that bio-enzyme degradation is small molecule, the HA polymers of small molecule, which can induce to have, exempts from
The maturing of the dendritic cells of epidemic disease effect, and promote dendritic cells to produce interleukin and TNF, play to dendron
The immune activation such as cell and macrophage, tumour cell is swallowed, and can be by influenceing immunocyte, cell factor
Activity plays its immunoregulation effect, and finally enters to have given play to vascularization, promote wound healing, be antitumor, immune
The physiological functions such as regulation.
The submucosal injection solution includes Sodium Hyaluronate 0.1-3.0 parts by weight, indicarminum 0.001-0.02 parts by weight and
Water 90-99 parts by weight.
Indicarminum is used as colouring agent, and is easy to observe ejection situation, effectively can be distinguished operative site and surrounding enviroment
Out, surgical field of view is highlighted, facilitates the disposable intactly removal of lesions of operator to reduce perforation without damaging muscularis propria
With the risk of the complication such as bleeding, ensure that operation is smoothed out.
The Sodium Hyaluronate molecular weight is the Da of 40-300 ten thousand.
The Da of Sodium Hyaluronate molecular weight 140-280 ten thousand.
Sodium Hyaluronate of the molecular weight for the Da of 140-280 ten thousand is used, after being expelled under mucous membrane, in addition to swelling effect well,
The propagation of cell and differentiation under mucous membrane can also be promoted, promote wound healing.
Also include adrenaline 0-0.005 parts by weight in the submucosal injection solution.
Adrenaline can rise cardiac contractile force, make heart, liver and the blood vessel dilatation of muscles and bones and skin, the blood of mucous membrane
Pipe shrinks.The adrenaline of addition 0-0.005 parts by weight can improve the blood pressure in surgical procedure in submucosal injection solution,
Improve success rate of operation.
Also include ascorbic acid 0-1 parts by weight in the submucosal injection solution.
Ascorbic acid is also known as vitamin C, is a kind of acid polyol containing 6 carbon atoms, and vitamin C has
Good antioxidation, carcinogenic substance N- nitroso compounds can be blocked to synthesize；Carcinogenic activation, pre- anti-cancer can be blocked
Disease.
Also include osmotic pressure regulator in the submucosal injection solution, the osmotic pressure regulator be sodium chloride, glycerine and
One or more in fructose.
Osmotic adjustment is the body fluid of one organism of active control osmotic pressure, to keep the water content of the organism of dynamic equilibrium,
This is that the liquid that it keeps also turns into dilution from organism or excessively concentrated.
Osmotic pressure regulator is glycerine 0-0.005 parts by weight and fructose 0-0.005 parts by weight in the submucosal injection solution.
Submucosal injection solution provided by the invention has advantages below：
1st, submucosal injection solution good fluidity provided by the invention, viscosity are that 5Pas-100Pas is relatively low, to lead to
Cross endoscopic injection pin and be expelled to submucosa, can cause to swell in submucosa, mucous layer is separated with muscularis propria, it is grand
30min-120min can be maintained by playing effect, ensure that operation is smoothly implemented；
2nd, submucosal injection solution provided by the invention uses indicarminum as colouring agent, and is easy to observe ejection situation, can have
Effectively operative site and surrounding enviroment are distinguished, highlight surgical field of view, facilitating operator, disposably intactly excision is sick
Stove reduces the risk of the complication such as perforation and bleeding, ensures that operation is smoothed out without damaging muscularis propria；
3rd, the Sodium Hyaluronate in submucosal injection provided by the invention can form macromolecular network structure and play machinery
Barrier iris action；There is a preferable lubrication, reduce esophagus, the foreign matter in stomach, enteron aisle is in wound healing process
Friction；Mitigate the infiltration of local inflammation reaction and inflammatory cell, mitigate and suppress bleeding and oozing of blood.Formed on serous coat
Diaphragm, and retain the long period, so that the serous coat of organ surface covering is preferably repaired；
4th, the Sodium Hyaluronate in submucosal injection provided by the invention is more for the HA of small molecule by bio-enzyme degradation in vivo
Aggressiveness catabolite, the HA polymers of small molecule can induce the maturing of the dendritic cells with immunization, and promote to set
Prominent cell produces interleukin and TNF, plays to immune activations such as dendritic cells and macrophages, swallows tumour
Cell, and can by influenceing immunocyte, the activity of cell factor plays its immunoregulation effect, and finally enters
Give play to vascularization, promote the physiological functions such as wound healing, antitumor, immunological regulation.
Embodiment
Embodiment 1
The parts by weight of Sodium Hyaluronate 0.2, the parts by weight of indicarminum 0.002 and the parts by weight of water 90 are well mixed, sticked
Solution is injected under film.Viscosity 13Pas, protuberance is held time 32min in mouse experiment.
Embodiment 2
By the parts by weight of Sodium Hyaluronate 0.5, the parts by weight of indicarminum 0.005, the parts by weight of adrenaline 0.001 and the weight of water 91
Amount part is well mixed, and obtains submucosal injection solution.Viscosity 28Pas, protuberance is held time 46min in mouse experiment.
Embodiment 3
By the parts by weight of Sodium Hyaluronate 1.0, the parts by weight of toluidine blue 0.01, the parts by weight of adrenaline 0.005 and water 99
Parts by weight are well mixed, and obtain submucosal injection solution.Viscosity 54Pas, protuberance is held time 47min in mouse experiment.
Embodiment 4
By the parts by weight of Sodium Hyaluronate 3.0, phenol red 0.001 parts by weight, the parts by weight of sodium chloride 0.8 and the parts by weight of water 95
It is well mixed, obtain submucosal injection solution.Viscosity 100Pas, protuberance is held time 120min in mouse experiment.
Embodiment 5
By the parts by weight of Sodium Hyaluronate 0.1, the parts by weight of crystal violet 0.02, the parts by weight of adrenaline 0.005, Vitamin C
Sour 0.1 parts by weight and the parts by weight of water 93 are well mixed, and obtain submucosal injection solution.Viscosity 5Pas, in mouse experiment
Swell the 30min that holds time.
Embodiment 6
By the parts by weight of Sodium Hyaluronate 2.0, Congo red 0.006 parts by weight, the parts by weight of adrenaline 0.003, Vitamin C
Sour 1.0 parts by weight, the parts by weight of sodium chloride 0.7 and the parts by weight of water 96 are well mixed, and obtain submucosal injection solution.Viscosity
73Pas, protuberance is held time 103min in mouse experiment.
Embodiment 7
By the parts by weight of Sodium Hyaluronate 2.5, phenol red 0.015 parts by weight, the parts by weight of adrenaline 0.003, ascorbic acid
0.5 parts by weight, the parts by weight of glycerine 10 and the parts by weight of water 91 are well mixed, and obtain submucosal injection solution.Viscosity 86Pas,
The 94min that holds time is swelled in mouse experiment.
Embodiment 8
By the parts by weight of Sodium Hyaluronate 0.6, the parts by weight of indicarminum 0.002, the parts by weight of adrenaline 0.002, Vitamin C
Sour 0.4 parts by weight, the parts by weight of sodium chloride 0.9 and the parts by weight of water 97 are well mixed, and obtain submucosal injection solution.Viscosity
25Pas, protuberance is held time 87min in mouse experiment.
Embodiment 9
By the parts by weight of Sodium Hyaluronate 0.8, the parts by weight of indicarminum 0.01, the parts by weight of adrenaline 0.001, Vitamin C
Sour 0.5 parts by weight, the parts by weight of sodium chloride 0.7, the parts by weight of glycerine 8, the parts by weight of fructose 4 and the mixing of the parts by weight of water 90 are equal
It is even, obtain submucosal injection solution.Viscosity 37Pas, protuberance is held time 96min in mouse experiment.
Embodiment 10
By the parts by weight of Sodium Hyaluronate 0.4, Congo red 0.01 parts by weight, the parts by weight of adrenaline 0.002, Vitamin C
Sour 0.8 parts by weight, the parts by weight of glycerine 9, the parts by weight of fructose 4.5 and the parts by weight of water 92 are well mixed, and obtain mucous membrane bet
Penetrate solution.Viscosity 21Pas, protuberance is held time 107min in mouse experiment.
Embodiments of the invention are described in detail above, but the content is only presently preferred embodiments of the present invention, no
The practical range for limiting the present invention can be considered as.Any changes and modifications in accordance with the scope of the present application,
All should still it belong within the patent covering scope of the present invention.
Claims (8)
1. submucosal injection solution, it is characterised in that：Including Sodium Hyaluronate 0.1-3.0 parts by weight, coloring agent 0.001-0.02
Parts by weight and water 90-99 parts by weight, the coloring agent are in indicarminum, toluidine blue, phenol red, Congo red, crystal violet
One or more.
2. submucosal injection solution according to claim 1, it is characterised in that：Including Sodium Hyaluronate 0.1-3.0
Parts by weight, indicarminum 0.001-0.02 parts by weight and water 90-99 parts by weight.
3. submucosal injection solution according to claim 1 or 2, it is characterised in that：The hyaluronic acid sodium molecule
Measure as the Da of 40-300 ten thousand.
4. submucosal injection solution according to claim 3, it is characterised in that：The Sodium Hyaluronate molecular weight
The Da of 140-280 ten thousand.
5. submucosal injection solution according to claim 4, it is characterised in that：Also wrapped in the submucosal injection solution
Include adrenaline 0-0.005 parts by weight.
6. submucosal injection solution according to claim 5, it is characterised in that：In the submucosal injection solution also
Including ascorbic acid 0-1 parts by weight.
7. submucosal injection solution according to claim 6, it is characterised in that：In the submucosal injection solution also
Including osmotic pressure regulator, the osmotic pressure regulator is the one or more in sodium chloride, glycerine and fructose.
8. submucosal injection solution according to claim 7, it is characterised in that：Oozed in the submucosal injection solution
Pressure conditioning agent is glycerine 0-0.005 parts by weight and fructose 0-0.005 parts by weight thoroughly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610389190.XA CN107456612A (en) | 2016-06-02 | 2016-06-02 | Submucosal injection solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610389190.XA CN107456612A (en) | 2016-06-02 | 2016-06-02 | Submucosal injection solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107456612A true CN107456612A (en) | 2017-12-12 |
Family
ID=60544721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610389190.XA Pending CN107456612A (en) | 2016-06-02 | 2016-06-02 | Submucosal injection solution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107456612A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020171212A1 (en) * | 2019-02-22 | 2020-08-27 | 生化学工業株式会社 | Method for improving storage stability |
| CN111803717A (en) * | 2020-06-12 | 2020-10-23 | 爱美客技术发展股份有限公司 | Preparation method and process of endomucosal injection swelling agent |
| CN113133996A (en) * | 2020-01-20 | 2021-07-20 | 山东威高药业股份有限公司 | Use of acetylcysteine or its chemically acceptable salt/ester in preparation of isolated preparation of connective tissue |
| WO2022065473A1 (en) * | 2020-09-28 | 2022-03-31 | テルモ株式会社 | Composition containing hyaluronic acid or salt thereof and indigocarmine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319260B1 (en) * | 2000-01-11 | 2001-11-20 | Hironori Yamamoto | Method of endoscopic mucosal resection using mucopolysaccharide and local injection preparation |
| CN105287626A (en) * | 2015-10-26 | 2016-02-03 | 张敏 | Mucosa injection |
-
2016
- 2016-06-02 CN CN201610389190.XA patent/CN107456612A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319260B1 (en) * | 2000-01-11 | 2001-11-20 | Hironori Yamamoto | Method of endoscopic mucosal resection using mucopolysaccharide and local injection preparation |
| CN105287626A (en) * | 2015-10-26 | 2016-02-03 | 张敏 | Mucosa injection |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020171212A1 (en) * | 2019-02-22 | 2020-08-27 | 生化学工業株式会社 | Method for improving storage stability |
| CN113382718A (en) * | 2019-02-22 | 2021-09-10 | 生化学工业株式会社 | Method for improving preservation performance |
| EP3928767A4 (en) * | 2019-02-22 | 2022-12-14 | Seikagaku Corporation | Method for improving storage stability |
| CN113382718B (en) * | 2019-02-22 | 2023-05-26 | 生化学工业株式会社 | Preservation performance improving method |
| CN113133996A (en) * | 2020-01-20 | 2021-07-20 | 山东威高药业股份有限公司 | Use of acetylcysteine or its chemically acceptable salt/ester in preparation of isolated preparation of connective tissue |
| WO2021147634A1 (en) * | 2020-01-20 | 2021-07-29 | 山东威高药业股份有限公司 | Application of acetylcysteine or chemically acceptable salt/ester thereof in preparation of connective tissue separation preparation |
| CN113133996B (en) * | 2020-01-20 | 2023-07-04 | 山东威高宏瑞医学科技有限公司 | Use of acetylcysteine or a chemically acceptable salt/ester thereof for producing isolated preparations of connective tissue |
| CN111803717A (en) * | 2020-06-12 | 2020-10-23 | 爱美客技术发展股份有限公司 | Preparation method and process of endomucosal injection swelling agent |
| WO2022065473A1 (en) * | 2020-09-28 | 2022-03-31 | テルモ株式会社 | Composition containing hyaluronic acid or salt thereof and indigocarmine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108498879B (en) | Composition and reagent combination for submucosal injection and application thereof | |
| US6319260B1 (en) | Method of endoscopic mucosal resection using mucopolysaccharide and local injection preparation | |
| US20220040093A1 (en) | Composition for use in the treatment of lesions in the mucosa by means of endoscopic resection | |
| CN107456612A (en) | Submucosal injection solution | |
| ES2957291T3 (en) | ECM Hydrogel for the Treatment of Esophageal Inflammation | |
| Tran et al. | Injectable drug-eluting elastomeric polymer: a novel submucosal injection material | |
| Kumano et al. | Endoscopic submucosal dissection for pig esophagus by using photocrosslinkable chitosan hydrogel as submucosal fluid cushion | |
| KR100799143B1 (en) | Injections for endoscopy | |
| CN114159586A (en) | Submucosal injection marker carrier gel for endoscope and application thereof | |
| KR20130079297A (en) | Thermosensitive injectable formulation comprising poloxamer 407 and poloxamer 188 | |
| KR101297363B1 (en) | Composition comprising local injection preparation for endoscopic mucosal resection | |
| CN110585489A (en) | Digestive tract submucosal injection swelling agent and application thereof | |
| CN114129714B (en) | Pharmaceutical preparation and preparation method and application thereof | |
| CN111110926B (en) | Injectable colored gel pad for alimentary canal mucosa layering and application thereof | |
| WO2021146291A1 (en) | Self-assembling peptide gel formulation and methods of use | |
| CN106267379A (en) | Hetastarch application in interior arthroscopic diagnosis | |
| CN115444993B (en) | Use of extracellular matrix (ECM) hydrogels as esophageal submucosa fluid pads | |
| Huang et al. | Treatment of benign prostatic hyperplasia using transurethral split of the prostate with a columnar balloon catheter | |
| WO2005037292A1 (en) | Mucous membrane bulging humor composition comprising chitosan derivative containing saccharide chain for use in condoscopic surgery | |
| RU2410035C1 (en) | Method of endoscopic hemostasis in gastroduodenal hemorrhages | |
| Kang et al. | Development of a hybrid hydrogel for submucosal injection in endoscopic resection of gastrointestinal neoplasm: From laboratory to clinical trial | |
| RU2535105C2 (en) | Method of treating angiodysplasias | |
| RU2295365C1 (en) | Laser therapy method for treating benign prostate hyperplasia cases | |
| RU2498800C2 (en) | Method for endoscopic hemostasis in gastric-duodenal hemorrhages | |
| CN114949377A (en) | Submucosal injection and application thereof in preparation of auxiliary agent for endoscopic submucosal dissection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171212 |
|
| WD01 | Invention patent application deemed withdrawn after publication |